CMG Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

102.57

P/S

2.79

EPS

19.40

Div Yield, %

—

Shrs. gr., 5y

-73.56%

Rev. gr., 5y

14.32%

Revenues

99.10b

+5.53%

Net income

2.69b

-58.26%

CFO

290m

-92.58%

Dividend

Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.

URL

http://cmgpharma.co.kr/

IPO date

Aug 31, 2001

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT